QUEBEC CITY, Dec. 14 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering lab services, announced a net loss from continuing operations of
$3,320,193 or $0.09 per share for the fourth quarter ending October 31, 2007,
and a net loss from continuing operations of $9,156,219 or $0.24 per share for
the fiscal year.